| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6263 |
Provisional Schedule
| Expected publication | 16 April 2025 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors | Merck Group |
| Department of Health and Social Care | |
| Health Technology Wales | |
| NHS England | |
| Patient carer groups | Multiple Sclerosis Trust |
| Multiple Sclerosis Society | |
| Professional groups | Association of British Neurologists |
| Royal College of Physicians | |
| Associated public health groups | Public Health Wales |
| UK Health Security Agency | |
| Comparator companies | Almirall (dimethyl fumarate) (not participating) |
| Axunio Pharma (teriflunomide) (not participating) | |
| Bayer (interferon beta 1-b) (not participating) | |
| Biogen Idec (dimethyl fumarate, interferon beta-1a, peginterferon beta-1a, diroximel fumarate) | |
| Celix Pharma (dimethyl fumarate) (not participating) | |
| Dr. Reddy’s Laboratories (teriflunomide) (not participating) | |
| Juvise Pharmaceuticals (ponesimod) | |
| Merck (interferon beta-1a) (not participating) | |
| Mylan (dimethyl fumarate, glatiramer acetate, teriflunomide) (not participating) | |
| Novartis (interferon beta-1b, ofatumumab, siponimod) | |
| Roche (ocrelizumab) | |
| Sandoz (teriflunomide) | |
| Sanofi Genzyme (teriflunomide) | |
| Teva UK (glatiramer acetate) (not participating) | |
| Zentiva (dimethyl fumarate) (not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| NHS Wales Joint Commissioning Committee | |
| Scottish Medicines Consortium | |
| Welsh Government |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 March 2025 - 26 March 2025 | Final draft guidance |
| 05 February 2025 | Committee meeting: 2 |
| 05 February 2025 | Declaration of interests |
| 04 February 2025 | Declaration of interests |
| 06 December 2024 - 09 January 2025 | Draft guidance |
| 13 November 2024 | Committee meeting: 1 |
| 22 April 2024 | Invitation to participate |
| 19 September 2023 - 17 October 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6263 |
| 03 August 2023 | In progress. DHSC referral received |
| 03 March 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual